Previous Oral Contraceptive Use and Breast Cancer Risk According to Hormone Replacement Therapy Use Among Postmenopausal Women

Overview

Journal Cancer Causes Control

Specialties Oncology
Public Health

Date 2005 Jun 30

PMID 15986108

Citations 4

Authors

Vanessa Dumeaux

Agnes Fournier

Eiliv Lund

Francoise Clavel-Chapelon

Affiliations

Soon will be listed here.

Abstract

Objective: To assess postmenopausal breast cancer risk in relation to particular patterns of oral contraceptive (OC) use according to hormone replacement therapy (HRT) exposure.

Methods: Time-dependent Cox regression models were used to analyse information on postmenopausal women from a large-scale French cohort. Among a total of 68,670 women born between 1925 and 1950, 1405 primary invasive postmenopausal breast cancer cases were identified from 1992 to 2000.

Results: A non-significant decrease in risk of around 10% was associated with ever OC use as compared to never OC use in postmenopausal women. No significant interaction was found between OC and HRT use on postmenopausal breast cancer risk. Breast cancer risk decreased significantly with increasing time since first OC use (test for trend: p=0.01); this was consistent after adjustment for duration of use or for time since last use.

Conclusion: No increase in breast cancer risk was associated with previous OC exposure among postmenopausal women, probably because the induction window had closed. Some women may develop breast cancer soon after exposure to OCs, leading to a deficit of cases of older women. Further investigation is therefore required to identify young women at high risk.

Citing Articles

Associations of Oral Contraceptives with Mammographic Breast Density in Premenopausal Women.

Yaghjyan L, Smotherman C, Heine J, Colditz G, Rosner B, Tamimi R Cancer Epidemiol Biomarkers Prev. 2021; 31(2):436-442.

PMID: 34862209 PMC: 8825703. DOI: 10.1158/1055-9965.EPI-21-0853.

Breast Cancer Risk and Insulin Resistance: Post Genome-Wide Gene-Environment Interaction Study Using a Random Survival Forest.

Jung S, Papp J, Sobel E, Yu H, Zhang Z Cancer Res. 2019; 79(10):2784-2794.

PMID: 30936085 PMC: 6522308. DOI: 10.1158/0008-5472.CAN-18-3688.

The Impact of Hormonal Contraceptives on Breast Cancer Pathology.

Dorchak J, Maria S, Guarinoni J, Duensing A, Somiari S, Cavanaugh J Horm Cancer. 2018; 9(4):240-253.

PMID: 29687205 PMC: 6742516. DOI: 10.1007/s12672-018-0332-y.

Exploring the human genome with functional maps.

Huttenhower C, Haley E, Hibbs M, Dumeaux V, Barrett D, Coller H Genome Res. 2009; 19(6):1093-106.

PMID: 19246570 PMC: 2694471. DOI: 10.1101/gr.082214.108.

References

Schairer C, Lubin J, Troisi R, Sturgeon S, Brinton L, Hoover R . Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. JAMA. 2000; 283(4):485-91. DOI: 10.1001/jama.283.4.485. View

Fournier A, Berrino F, Riboli E, Avenel V, Clavel-Chapelon F . Breast cancer risk in relation to different types of hormone replacement therapy in the E3N-EPIC cohort. Int J Cancer. 2004; 114(3):448-54. DOI: 10.1002/ijc.20710. View

Clemons M, Goss P . Estrogen and the risk of breast cancer. N Engl J Med. 2001; 344(4):276-85. DOI: 10.1056/NEJM200101253440407. View

Ursin G, Tseng C, Paganini-Hill A, Enger S, Wan P, Formenti S . Does menopausal hormone replacement therapy interact with known factors to increase risk of breast cancer?. J Clin Oncol. 2002; 20(3):699-706. DOI: 10.1200/JCO.2002.20.3.699. View

Marchbanks P, McDonald J, Wilson H, Folger S, Mandel M, Daling J . Oral contraceptives and the risk of breast cancer. N Engl J Med. 2002; 346(26):2025-32. DOI: 10.1056/NEJMoa013202. View

Rossouw J, Anderson G, Prentice R, LaCroix A, Kooperberg C, Stefanick M . Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA. 2002; 288(3):321-33. DOI: 10.1001/jama.288.3.321. View

Kumle M, Weiderpass E, Braaten T, Persson I, Adami H, Lund E . Use of oral contraceptives and breast cancer risk: The Norwegian-Swedish Women's Lifestyle and Health Cohort Study. Cancer Epidemiol Biomarkers Prev. 2002; 11(11):1375-81. View

Althuis M, Brogan D, Coates R, Daling J, Gammon M, Malone K . Hormonal content and potency of oral contraceptives and breast cancer risk among young women. Br J Cancer. 2003; 88(1):50-7. PMC: 2376784. DOI: 10.1038/sj.bjc.6600691. View

Althuis M, Brogan D, Coates R, Daling J, Gammon M, Malone K . Breast cancers among very young premenopausal women (United States). Cancer Causes Control. 2003; 14(2):151-60. DOI: 10.1023/a:1023006000760. View

10.

Dumeaux V, Alsaker E, Lund E . Breast cancer and specific types of oral contraceptives: a large Norwegian cohort study. Int J Cancer. 2003; 105(6):844-50. DOI: 10.1002/ijc.11167. View

11.

Beral V . Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet. 2003; 362(9382):419-27. DOI: 10.1016/s0140-6736(03)14065-2. View

12.

Norman S, Berlin J, Weber A, Strom B, Daling J, Weiss L . Combined effect of oral contraceptive use and hormone replacement therapy on breast cancer risk in postmenopausal women. Cancer Causes Control. 2004; 14(10):933-43. DOI: 10.1023/b:caco.0000007967.25865.29. View

13.

Bakken K, Alsaker E, Eggen A, Lund E . Hormone replacement therapy and incidence of hormone-dependent cancers in the Norwegian Women and Cancer study. Int J Cancer. 2004; 112(1):130-4. DOI: 10.1002/ijc.20389. View

14.

Whittemore A . The age distribution of human cancer for carcinogenic exposures of varying intensity. Am J Epidemiol. 1977; 106(5):418-32. DOI: 10.1093/oxfordjournals.aje.a112484. View

15.

McPherson K, Vessey M, Neil A, DOLL R, Jones L, Roberts M . Early oral contraceptive use and breast cancer: results of another case-control study. Br J Cancer. 1987; 56(5):653-60. PMC: 2001913. DOI: 10.1038/bjc.1987.261. View

16.

Riboli E . Nutrition and cancer: background and rationale of the European Prospective Investigation into Cancer and Nutrition (EPIC). Ann Oncol. 1992; 3(10):783-91. DOI: 10.1093/oxfordjournals.annonc.a058097. View

17.

Wingo P, Lee N, Ory H, Beral V, Peterson H, Rhodes P . Age-specific differences in the relationship between oral contraceptive use and breast cancer. Cancer. 1993; 71(4 Suppl):1506-17. DOI: 10.1002/cncr.2820710416. View

18.

White E, Malone K, Weiss N, Daling J . Breast cancer among young U.S. women in relation to oral contraceptive use. J Natl Cancer Inst. 1994; 86(7):505-14. DOI: 10.1093/jnci/86.7.505. View

19.

Altman D, De Stavola B . Practical problems in fitting a proportional hazards model to data with updated measurements of the covariates. Stat Med. 1994; 13(4):301-41. DOI: 10.1002/sim.4780130402. View

20.

Rookus M, van Leeuwen F . Oral contraceptives and risk of breast cancer in women aged 20-54 years. Netherlands Oral Contraceptives and Breast Cancer Study Group. Lancet. 1994; 344(8926):844-51. DOI: 10.1016/s0140-6736(94)92826-6. View